HIMS Blowout Q3 Leads To Substantial Fair Value Bump

Hims & Hers delivered yet another blowout result for Q3 - this one the most impressive yet. Revenue growth accelerated to 77%, on the back of both the GLP-1 weight loss drug launch, and the 44% subscriber growth it helped drive. Even ex-GLP sales, revenues soared 40%. The weight loss drug launch has also supercharged the Hers brand, giving the company yet another growth avenue. The stock is up over 150% since we added it a year ago, but now looks like as good a time as ever to add. The fair value gets a substantial bump from $21 to $28.

Watch List

S 13.51%
NTNX 16.61%
CRWD 78.83%
SEMR 12.90%
SNOW 21.89%
SE 54.36%
TSM -4.32%

Buy List

GOOG -33.41%
NYAX -52.11%
ASR -28.26%
PAYC -26.58%
HRMY -43.75%
YOU -50.92%
MELI -25.17%
ADBE -32.31%

Hold List

ZETA -24.57%
MSFT -21.56%
ODD -23.27%
FLYW -2.39%
CELH -20.69%
TOST 35.09%
CPNG -3.40%
HIMS 8.96%
MNDY 17.13%
GLBE 23.47%
ZS 21.04%
V -7.33%
ADSK 12.01%
NOW 57.76%
ABNB -22.78%
FTNT 4.05%
TEAM 19.64%